

**FITC anti-human CD304 (Neuropilin-1)**

**Catalog # / Size:** 2372560 / 100 tests  
2372555 / 25 tests

**Clone:** 12C2

**Isotype:** Mouse IgG2a, κ


**Immunogen:** CD304-Fc Fusion protein

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).


**Concentration:** Lot-specific



**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Human peripheral blood mononuclear cells were stained with CD303 APC and CD304 (clone 12C2) FITC (top) or mouse IgG2a, κ FITC isotype control (bottom). Data shown was gated on the lymphocyte and monocyte populations.

**Description:** CD304, also known as neuropilin-1, BDCA-4 and VEGF165R, is a 140 kD type I transmembrane protein. Its extracellular region contains 2 CUB, 2 FV/FVIII, and one MAM domain; a soluble isoform is produced by alternative mRNA splicing. CD304 is involved in angiogenesis, neural development, and tumor metastasis. It's expressed by plasmacytoid dendritic cells, thymocytes, neurons, endothelium, and a subset of T<sub>FH</sub> cells. CD304 is also expressed in several carcinomas, and a high expression of this molecule in prostate cancer correlates with a poor prognosis.

- Antigen References:**
1. Mizui M and Kikutani H. 2008. *Immunity* 28:302.
  2. Hamerlik P, et al. 2012. *J. Exp. Med.* 209:507.
  3. Karjalainen K, et al. 2011. *Blood* 117:920.
  4. Lepelletier Y, et al. 2007.

